[
  {
    "id": "DRUG-001",
    "category": "drug_treatment",
    "difficulty": "easy",
    "question": "What drugs are FDA-approved for treating ALS?",
    "prompt_template": "List the FDA-approved drugs for ALS treatment and when they were approved.",
    "verified_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
    "key_facts": ["riluzole", "edaravone", "1995", "2017"],
    "source": {"type": "pubmed", "id": "PMC6344461", "corpus_ref": "fda-approved als drugs riluzole edaravone"},
    "is_trap": false
  },
  {
    "id": "DRUG-002",
    "category": "drug_treatment",
    "difficulty": "medium",
    "question": "What is the mechanism of action of riluzole in ALS?",
    "prompt_template": "Explain how riluzole works to treat ALS at the molecular level.",
    "verified_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
    "key_facts": ["glutamate release inhibitor", "excitotoxicity", "sodium channels", "motor neuron protection"],
    "source": {"type": "pubmed", "id": "PMC4442073", "corpus_ref": "riluzole mechanism glutamate"},
    "is_trap": false
  },
  {
    "id": "DRUG-003",
    "category": "drug_treatment",
    "difficulty": "medium",
    "question": "What is edaravone and how does it work in treating ALS?",
    "prompt_template": "Describe the mechanism of action of edaravone (Radicava) in ALS treatment.",
    "verified_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
    "key_facts": ["free radical scavenger", "oxidative stress", "radicava", "alsfrs-r"],
    "source": {"type": "pubmed", "id": "PMC5726029", "corpus_ref": "edaravone radicava free radical"},
    "is_trap": false
  },
  {
    "id": "DRUG-004",
    "category": "drug_treatment",
    "difficulty": "easy",
    "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
    "prompt_template": "Name the drug prescribed for pseudobulbar affect (uncontrollable laughing or crying) in ALS patients.",
    "verified_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
    "key_facts": ["nuedexta", "dextromethorphan", "quinidine", "pseudobulbar affect"],
    "source": {"type": "pubmed", "id": "PMC3109288", "corpus_ref": "pseudobulbar affect nuedexta dextromethorphan"},
    "is_trap": false
  },
  {
    "id": "DRUG-005",
    "category": "drug_treatment",
    "difficulty": "medium",
    "question": "What is baclofen used for in ALS management?",
    "prompt_template": "Explain the role of baclofen in managing ALS symptoms.",
    "verified_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
    "key_facts": ["spasticity", "gaba-b receptor agonist", "upper motor neuron", "muscle stiffness"],
    "source": {"type": "guideline", "id": "AAN ALS practice parameter", "corpus_ref": "baclofen spasticity als management"},
    "is_trap": false
  },
  {
    "id": "DRUG-006",
    "category": "drug_treatment",
    "difficulty": "hard",
    "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
    "prompt_template": "Describe the results of the Bensimon et al. pivotal trial of riluzole in ALS.",
    "verified_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
    "key_facts": ["bensimon", "double-blind placebo-controlled", "100 mg per day", "survival benefit 2-3 months"],
    "source": {"type": "pubmed", "id": "PMC1073024", "corpus_ref": "bensimon riluzole trial 1994"},
    "is_trap": false
  },
  {
    "id": "DRUG-007",
    "category": "drug_treatment",
    "difficulty": "hard",
    "question": "What is tofersen and for which ALS population is it indicated?",
    "prompt_template": "Describe tofersen, its mechanism, and the specific ALS patient population it targets.",
    "verified_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
    "key_facts": ["antisense oligonucleotide", "sod1 mutations", "intrathecal administration", "qalsody"],
    "source": {"type": "pubmed", "id": "PMC9981234", "corpus_ref": "tofersen sod1 antisense oligonucleotide"},
    "is_trap": false
  },
  {
    "id": "DRUG-008",
    "category": "drug_treatment",
    "difficulty": "easy",
    "question": "What are common side effects of riluzole?",
    "prompt_template": "List the common adverse effects associated with riluzole use in ALS patients.",
    "verified_answer": "Common side effects of riluzole include nausea, asthenia (general weakness), elevated liver enzymes (hepatotoxicity requiring liver function monitoring), dizziness, and gastrointestinal disturbances. Regular monitoring of liver function tests is recommended, typically every month for the first three months and then periodically thereafter.",
    "key_facts": ["nausea", "elevated liver enzymes", "asthenia", "liver function monitoring"],
    "source": {"type": "pubmed", "id": "PMC4442073", "corpus_ref": "riluzole side effects hepatotoxicity"},
    "is_trap": false
  },
  {
    "id": "DRUG-009",
    "category": "drug_treatment",
    "difficulty": "hard",
    "question": "What is AMX0035 and what was the outcome of the CENTAUR trial?",
    "prompt_template": "Describe AMX0035 (Relyvrio) and the results of the CENTAUR clinical trial for ALS.",
    "verified_answer": "AMX0035 (brand name Relyvrio, later withdrawn from market) is a combination of sodium phenylbutyrate and taurursodiol (TURSO) that targets endoplasmic reticulum stress and mitochondrial dysfunction. The CENTAUR trial showed a modest slowing of functional decline on the ALSFRS-R scale compared to placebo over 24 weeks. However, the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint, and the drug was voluntarily withdrawn from the market in 2024.",
    "key_facts": ["sodium phenylbutyrate", "taurursodiol", "centaur trial", "alsfrs-r decline"],
    "source": {"type": "pubmed", "id": "PMC7682365", "corpus_ref": "amx0035 centaur trial phenylbutyrate"},
    "is_trap": false
  },
  {
    "id": "DRUG-010",
    "category": "drug_treatment",
    "difficulty": "medium",
    "question": "What is masitinib and what is its proposed mechanism in ALS?",
    "prompt_template": "Describe masitinib and explain how it is proposed to help in ALS treatment.",
    "verified_answer": "Masitinib is not a real approved ALS treatment. While masitinib is a tyrosine kinase inhibitor that has been investigated in some clinical trials for various conditions, there is no confirmed drug called 'masitinib' with an established approval for ALS. This question tests whether the model fabricates clinical trial details about investigational compounds.",
    "key_facts": ["tyrosine kinase inhibitor", "investigational", "not fda-approved for als", "neuroinflammation"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "GENE-001",
    "category": "gene_mutation",
    "difficulty": "easy",
    "question": "What is the most common genetic cause of familial ALS?",
    "prompt_template": "Identify the most frequently mutated gene in familial ALS cases.",
    "verified_answer": "The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of familial ALS, accounting for approximately 40% of familial cases and about 5-10% of apparently sporadic cases in European populations. The mutation involves a GGGGCC repeat expansion in the first intron of the C9orf72 gene on chromosome 9p21.",
    "key_facts": ["c9orf72", "hexanucleotide repeat expansion", "40% of familial als", "chromosome 9"],
    "source": {"type": "pubmed", "id": "PMC3268536", "corpus_ref": "c9orf72 repeat expansion familial als"},
    "is_trap": false
  },
  {
    "id": "GENE-002",
    "category": "gene_mutation",
    "difficulty": "medium",
    "question": "What is the SOD1 gene and how do its mutations cause ALS?",
    "prompt_template": "Explain the role of SOD1 mutations in ALS pathogenesis.",
    "verified_answer": "SOD1 (superoxide dismutase 1) encodes a copper-zinc superoxide dismutase enzyme that converts superoxide radicals to hydrogen peroxide and oxygen. Over 180 different mutations in SOD1 have been identified in ALS patients, accounting for about 12-20% of familial ALS and 1-2% of sporadic ALS. The mutations cause disease primarily through a toxic gain-of-function mechanism involving protein misfolding and aggregation, rather than loss of enzymatic activity.",
    "key_facts": ["superoxide dismutase 1", "toxic gain of function", "protein misfolding", "12-20% of familial als"],
    "source": {"type": "pubmed", "id": "PMC4090909", "corpus_ref": "sod1 mutations als gain of function"},
    "is_trap": false
  },
  {
    "id": "GENE-003",
    "category": "gene_mutation",
    "difficulty": "medium",
    "question": "What is the TARDBP gene and what protein does it encode?",
    "prompt_template": "Describe the TARDBP gene, its protein product, and its role in ALS.",
    "verified_answer": "TARDBP encodes the TAR DNA-binding protein 43 (TDP-43), a nuclear RNA-binding protein involved in RNA processing, splicing, and transport. Mutations in TARDBP account for approximately 4-5% of familial ALS cases. TDP-43 pathology (cytoplasmic mislocalization and aggregation) is the hallmark pathological finding in approximately 97% of all ALS cases, regardless of genetic cause.",
    "key_facts": ["tdp-43", "rna-binding protein", "cytoplasmic mislocalization", "97% of als cases"],
    "source": {"type": "pubmed", "id": "PMC5427689", "corpus_ref": "tardbp tdp-43 als pathology"},
    "is_trap": false
  },
  {
    "id": "GENE-004",
    "category": "gene_mutation",
    "difficulty": "hard",
    "question": "What is the FUS gene and how do its mutations contribute to ALS?",
    "prompt_template": "Explain the function of FUS and how FUS mutations lead to ALS.",
    "verified_answer": "FUS (fused in sarcoma) encodes an RNA-binding protein involved in transcription, RNA splicing, and DNA repair. Mutations in FUS account for approximately 4-5% of familial ALS cases and are often associated with younger age of onset. FUS mutations cause cytoplasmic mislocalization of the protein, leading to formation of stress granules and toxic aggregates. Unlike most ALS cases, FUS-ALS typically does not show TDP-43 pathology but instead shows FUS-positive inclusions.",
    "key_facts": ["rna-binding protein", "cytoplasmic mislocalization", "younger onset", "fus-positive inclusions"],
    "source": {"type": "pubmed", "id": "PMC2892552", "corpus_ref": "fus mutations als rna binding"},
    "is_trap": false
  },
  {
    "id": "GENE-005",
    "category": "gene_mutation",
    "difficulty": "easy",
    "question": "What percentage of ALS cases are familial versus sporadic?",
    "prompt_template": "State the proportion of ALS cases that are familial (inherited) versus sporadic.",
    "verified_answer": "Approximately 5-10% of ALS cases are familial (inherited), while 90-95% are sporadic with no clear family history. However, the boundary between familial and sporadic ALS has become blurred as genetic testing has identified disease-causing mutations in some apparently sporadic cases, particularly C9orf72 repeat expansions.",
    "key_facts": ["5-10% familial", "90-95% sporadic", "genetic overlap", "c9orf72 in sporadic cases"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "familial sporadic als percentage"},
    "is_trap": false
  },
  {
    "id": "GENE-006",
    "category": "gene_mutation",
    "difficulty": "hard",
    "question": "What is the TBK1 gene and what is its role in ALS?",
    "prompt_template": "Describe TBK1 and explain its connection to ALS pathogenesis.",
    "verified_answer": "TBK1 (TANK-binding kinase 1) is a serine/threonine kinase involved in innate immunity and autophagy pathways. Loss-of-function mutations in TBK1 are associated with ALS and frontotemporal dementia (FTD). TBK1 phosphorylates optineurin (OPTN) and p62/SQSTM1, which are both involved in selective autophagy and clearance of protein aggregates. TBK1 mutations account for approximately 1-2% of familial ALS cases.",
    "key_facts": ["serine/threonine kinase", "autophagy", "frontotemporal dementia", "optineurin phosphorylation"],
    "source": {"type": "pubmed", "id": "PMC4559105", "corpus_ref": "tbk1 als autophagy innate immunity"},
    "is_trap": false
  },
  {
    "id": "GENE-007",
    "category": "gene_mutation",
    "difficulty": "medium",
    "question": "How does the C9orf72 repeat expansion cause disease?",
    "prompt_template": "Explain the molecular mechanisms by which the C9orf72 hexanucleotide repeat expansion causes ALS.",
    "verified_answer": "The C9orf72 GGGGCC repeat expansion causes disease through three proposed mechanisms: (1) loss of function due to reduced C9orf72 protein expression from the expanded allele, affecting autophagy and endosomal trafficking; (2) RNA toxicity from repeat-containing RNA transcripts that form nuclear RNA foci and sequester RNA-binding proteins; and (3) toxic dipeptide repeat (DPR) proteins produced by repeat-associated non-ATG (RAN) translation of the expanded repeat in all reading frames.",
    "key_facts": ["loss of function", "rna foci", "dipeptide repeat proteins", "ran translation"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "c9orf72 mechanism rna foci dipeptide repeat"},
    "is_trap": false
  },
  {
    "id": "GENE-008",
    "category": "gene_mutation",
    "difficulty": "easy",
    "question": "What protein does the SOD1 gene encode?",
    "prompt_template": "Name the protein product of the SOD1 gene and describe its normal function.",
    "verified_answer": "The SOD1 gene encodes superoxide dismutase 1 (also known as Cu/Zn superoxide dismutase), a cytoplasmic enzyme that catalyzes the conversion of superoxide radicals (O2-) into hydrogen peroxide (H2O2) and molecular oxygen. This enzyme is a critical component of the cell's antioxidant defense system.",
    "key_facts": ["superoxide dismutase 1", "copper-zinc", "antioxidant defense", "converts superoxide to hydrogen peroxide"],
    "source": {"type": "pubmed", "id": "PMC4090909", "corpus_ref": "sod1 superoxide dismutase enzyme function"},
    "is_trap": false
  },
  {
    "id": "GENE-009",
    "category": "gene_mutation",
    "difficulty": "hard",
    "question": "What is the BRCA3 gene's role in ALS pathogenesis?",
    "prompt_template": "Describe the function of BRCA3 and its contribution to ALS.",
    "verified_answer": "There is no gene called BRCA3 that is associated with ALS. The BRCA gene family (BRCA1, BRCA2) is associated with breast and ovarian cancer susceptibility, not ALS. This is a fabricated association. The major ALS-associated genes include SOD1, C9orf72, TARDBP, FUS, and TBK1.",
    "key_facts": ["no such gene associated with als", "brca genes relate to cancer", "fabricated association"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "GENE-010",
    "category": "gene_mutation",
    "difficulty": "medium",
    "question": "What is the genetic relationship between ALS and frontotemporal dementia?",
    "prompt_template": "Explain the genetic overlap between ALS and frontotemporal dementia (FTD).",
    "verified_answer": "ALS and frontotemporal dementia (FTD) share significant genetic overlap and are increasingly viewed as a disease spectrum. The C9orf72 repeat expansion is the most common shared genetic cause, found in both ALS and FTD families. Other shared genes include TARDBP, FUS, VCP, UBQLN2, and TBK1. Approximately 15% of ALS patients also develop FTD, and up to 50% show some cognitive or behavioral impairment.",
    "key_facts": ["disease spectrum", "c9orf72 shared cause", "15% als patients develop ftd", "tardbp and fus shared"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als ftd genetic overlap spectrum"},
    "is_trap": false
  },
  {
    "id": "DIAG-001",
    "category": "diagnostic_criteria",
    "difficulty": "medium",
    "question": "What are the El Escorial criteria for diagnosing ALS?",
    "prompt_template": "Describe the El Escorial diagnostic criteria for ALS and its classification levels.",
    "verified_answer": "The El Escorial criteria, established by the World Federation of Neurology in 1994 (revised 1998), classify ALS diagnosis into levels based on clinical evidence of upper motor neuron (UMN) and lower motor neuron (LMN) signs across four body regions (bulbar, cervical, thoracic, lumbosacral). The levels are: definite (UMN + LMN signs in 3 regions), probable (UMN + LMN in 2 regions with UMN rostral to LMN), probable laboratory-supported (UMN + LMN in 1 region with EMG evidence), and possible (UMN + LMN in 1 region).",
    "key_facts": ["upper motor neuron and lower motor neuron signs", "four body regions", "definite probable possible", "world federation of neurology"],
    "source": {"type": "guideline", "id": "El Escorial criteria WFN 1994/1998", "corpus_ref": "el escorial criteria umn lmn regions"},
    "is_trap": false
  },
  {
    "id": "DIAG-002",
    "category": "diagnostic_criteria",
    "difficulty": "hard",
    "question": "How do the Awaji criteria differ from the El Escorial criteria?",
    "prompt_template": "Compare the Awaji-shima criteria with the revised El Escorial criteria for ALS diagnosis.",
    "verified_answer": "The Awaji-shima criteria (2008) modified the El Escorial criteria by treating electrophysiological evidence (EMG findings) as equivalent to clinical examination for detecting lower motor neuron involvement. This means fasciculation potentials on EMG combined with chronic neurogenic changes are accepted as evidence of LMN degeneration, equal to clinical signs. This change increased diagnostic sensitivity, particularly for bulbar-onset ALS, without significantly reducing specificity.",
    "key_facts": ["emg equivalent to clinical examination", "fasciculation potentials accepted", "increased diagnostic sensitivity", "2008"],
    "source": {"type": "pubmed", "id": "PMC2763620", "corpus_ref": "awaji criteria emg equivalence fasciculation"},
    "is_trap": false
  },
  {
    "id": "DIAG-003",
    "category": "diagnostic_criteria",
    "difficulty": "easy",
    "question": "What are upper motor neuron signs in ALS?",
    "prompt_template": "List the clinical signs of upper motor neuron involvement in ALS.",
    "verified_answer": "Upper motor neuron (UMN) signs in ALS include hyperreflexia (exaggerated deep tendon reflexes), spasticity (increased muscle tone), pathological reflexes such as the Babinski sign (extensor plantar response), Hoffmann sign, clonus, and pseudobulbar affect (emotional lability). These signs result from degeneration of corticospinal and corticobulbar motor neurons.",
    "key_facts": ["hyperreflexia", "spasticity", "babinski sign", "pseudobulbar affect"],
    "source": {"type": "textbook", "id": "Adams and Victor Principles of Neurology", "corpus_ref": "upper motor neuron signs als hyperreflexia"},
    "is_trap": false
  },
  {
    "id": "DIAG-004",
    "category": "diagnostic_criteria",
    "difficulty": "easy",
    "question": "What are lower motor neuron signs in ALS?",
    "prompt_template": "List the clinical signs of lower motor neuron involvement in ALS.",
    "verified_answer": "Lower motor neuron (LMN) signs in ALS include muscle weakness, muscle atrophy (wasting), fasciculations (visible muscle twitching), hyporeflexia or areflexia (reduced or absent deep tendon reflexes), and muscle cramps. These signs result from degeneration of anterior horn cells in the spinal cord and motor nuclei in the brainstem.",
    "key_facts": ["muscle weakness", "muscle atrophy", "fasciculations", "hyporeflexia"],
    "source": {"type": "textbook", "id": "Adams and Victor Principles of Neurology", "corpus_ref": "lower motor neuron signs fasciculations atrophy"},
    "is_trap": false
  },
  {
    "id": "DIAG-005",
    "category": "diagnostic_criteria",
    "difficulty": "medium",
    "question": "What EMG findings are characteristic of ALS?",
    "prompt_template": "Describe the electromyography (EMG) findings typically seen in ALS patients.",
    "verified_answer": "Characteristic EMG findings in ALS include widespread denervation evidenced by fibrillation potentials and positive sharp waves at rest, fasciculation potentials, and chronic reinnervation changes including large-amplitude, long-duration motor unit action potentials (MUAPs) with polyphasic morphology. These findings should be present in multiple body regions to support the diagnosis. Reduced recruitment of motor units is also typically observed.",
    "key_facts": ["fibrillation potentials", "fasciculation potentials", "large motor unit action potentials", "multiple body regions"],
    "source": {"type": "pubmed", "id": "PMC2763620", "corpus_ref": "emg als fibrillation fasciculation denervation"},
    "is_trap": false
  },
  {
    "id": "DIAG-006",
    "category": "diagnostic_criteria",
    "difficulty": "hard",
    "question": "What are the Gold Coast criteria for ALS diagnosis?",
    "prompt_template": "Describe the Gold Coast criteria and how they simplify ALS diagnosis compared to earlier criteria.",
    "verified_answer": "The Gold Coast criteria (2019) simplified ALS diagnosis by requiring: (1) progressive motor impairment documented by history or clinical examination, (2) presence of upper and/or lower motor neuron dysfunction on examination (with EMG as equivalent for LMN), and (3) exclusion of alternative diagnoses by investigations. Unlike El Escorial, the Gold Coast criteria eliminated the requirement for combined UMN and LMN signs, accepting isolated LMN disease with progressive course. This significantly improved sensitivity for diagnosing patients who present without UMN signs.",
    "key_facts": ["simplified diagnosis", "progressive motor impairment", "umn and/or lmn dysfunction", "eliminated combined umn lmn requirement"],
    "source": {"type": "pubmed", "id": "PMC6872439", "corpus_ref": "gold coast criteria simplified als diagnosis"},
    "is_trap": false
  },
  {
    "id": "DIAG-007",
    "category": "diagnostic_criteria",
    "difficulty": "medium",
    "question": "What conditions must be excluded in the differential diagnosis of ALS?",
    "prompt_template": "List the key conditions that must be ruled out when diagnosing ALS.",
    "verified_answer": "Key conditions in the ALS differential diagnosis include cervical spondylotic myelopathy, multifocal motor neuropathy with conduction block, Kennedy disease (spinal and bulbar muscular atrophy), primary lateral sclerosis, spinal muscular atrophy, myasthenia gravis, inclusion body myositis, and benign fasciculation syndrome. Structural spinal cord lesions, paraneoplastic syndromes, and heavy metal toxicity should also be excluded.",
    "key_facts": ["cervical spondylotic myelopathy", "multifocal motor neuropathy", "kennedy disease", "myasthenia gravis"],
    "source": {"type": "guideline", "id": "AAN practice parameter differential diagnosis", "corpus_ref": "als differential diagnosis mimics"},
    "is_trap": false
  },
  {
    "id": "DIAG-008",
    "category": "diagnostic_criteria",
    "difficulty": "medium",
    "question": "What is Kennedy disease and how does it differ from ALS?",
    "prompt_template": "Describe Kennedy disease and explain how it is distinguished from ALS.",
    "verified_answer": "Kennedy disease (spinal and bulbar muscular atrophy, SBMA) is an X-linked recessive motor neuron disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor gene. It differs from ALS in that it is slowly progressive with a much longer survival (decades vs. 2-5 years for ALS), predominantly affects lower motor neurons with no UMN signs, features gynecomastia and androgen insensitivity, and is genetically confirmed. It exclusively affects males.",
    "key_facts": ["x-linked recessive", "androgen receptor gene", "slowly progressive", "no upper motor neuron signs"],
    "source": {"type": "pubmed", "id": "PMC3567829", "corpus_ref": "kennedy disease sbma androgen receptor"},
    "is_trap": false
  },
  {
    "id": "DIAG-009",
    "category": "diagnostic_criteria",
    "difficulty": "hard",
    "question": "What are the diagnostic criteria for the Brainbridge classification of ALS subtypes?",
    "prompt_template": "Describe the Brainbridge classification system for ALS diagnostic subtypes.",
    "verified_answer": "There is no recognized ALS classification system called the 'Brainbridge classification.' The established diagnostic classification systems for ALS include the El Escorial criteria (1994, revised 1998), the Awaji-shima criteria (2008), and the Gold Coast criteria (2019). This is a fabricated classification name.",
    "key_facts": ["no such classification exists", "fabricated name", "el escorial awaji gold coast are real criteria"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "DIAG-010",
    "category": "diagnostic_criteria",
    "difficulty": "easy",
    "question": "What is the typical time from symptom onset to ALS diagnosis?",
    "prompt_template": "State the average diagnostic delay from first symptoms to confirmed ALS diagnosis.",
    "verified_answer": "The average time from symptom onset to ALS diagnosis is approximately 10-16 months, though some patients experience diagnostic delays of up to 2 years or more. The delay is often due to the insidious onset of symptoms, initial misdiagnosis, referral patterns, and the requirement to exclude other conditions. Earlier diagnosis is an active area of research focus.",
    "key_facts": ["10-16 months average", "diagnostic delay", "insidious onset", "exclusion of other conditions"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als diagnostic delay time to diagnosis"},
    "is_trap": false
  },
  {
    "id": "TRIAL-001",
    "category": "clinical_trials",
    "difficulty": "medium",
    "question": "What is the ALSFRS-R and why is it important in clinical trials?",
    "prompt_template": "Describe the ALSFRS-R scale and explain its role in ALS clinical trials.",
    "verified_answer": "The ALS Functional Rating Scale-Revised (ALSFRS-R) is a 12-item questionnaire that measures functional disability in ALS patients across four domains: bulbar function, fine motor function, gross motor function, and respiratory function. Each item is scored 0-4, giving a total score of 0-48 (48 = normal function). It is the most widely used primary outcome measure in ALS clinical trials because it tracks disease progression across multiple functional domains and correlates with survival.",
    "key_facts": ["12-item questionnaire", "score 0-48", "four domains", "primary outcome measure in trials"],
    "source": {"type": "pubmed", "id": "PMC4441750", "corpus_ref": "alsfrs-r functional rating scale clinical trials"},
    "is_trap": false
  },
  {
    "id": "TRIAL-002",
    "category": "clinical_trials",
    "difficulty": "hard",
    "question": "What was the design and outcome of the VALOR tofersen trial?",
    "prompt_template": "Describe the VALOR trial design for tofersen in SOD1-ALS and its key results.",
    "verified_answer": "The VALOR trial was a Phase 3, randomized, double-blind, placebo-controlled study of tofersen (an antisense oligonucleotide targeting SOD1 mRNA) in patients with SOD1-mutant ALS. The primary endpoint was change in ALSFRS-R over 28 weeks. While the trial did not meet its primary endpoint of a statistically significant difference in ALSFRS-R decline, it showed significant reduction of SOD1 protein levels in cerebrospinal fluid and neurofilament light chain (NfL) levels, supporting its biological mechanism.",
    "key_facts": ["phase 3 double-blind", "sod1-mutant als patients", "did not meet primary endpoint", "reduced sod1 protein and neurofilament levels"],
    "source": {"type": "nct", "id": "NCT02623699", "corpus_ref": "valor tofersen sod1 trial primary endpoint"},
    "is_trap": false
  },
  {
    "id": "TRIAL-003",
    "category": "clinical_trials",
    "difficulty": "medium",
    "question": "What are the most common primary endpoints used in ALS clinical trials?",
    "prompt_template": "List and explain the primary efficacy endpoints typically used in ALS clinical trials.",
    "verified_answer": "The most common primary endpoints in ALS clinical trials include: (1) ALSFRS-R score change (functional decline rate), (2) survival or tracheostomy-free survival, (3) forced vital capacity (FVC) as a measure of respiratory function decline, and (4) time to specified events such as loss of ambulation or ventilator dependence. More recently, neurofilament light chain (NfL) levels have been explored as pharmacodynamic biomarkers.",
    "key_facts": ["alsfrs-r score change", "survival", "forced vital capacity", "neurofilament light chain"],
    "source": {"type": "review", "id": "ALS clinical trial design review", "corpus_ref": "als trial endpoints alsfrs-r survival fvc"},
    "is_trap": false
  },
  {
    "id": "TRIAL-004",
    "category": "clinical_trials",
    "difficulty": "easy",
    "question": "What was the pivotal clinical trial that led to riluzole's FDA approval?",
    "prompt_template": "Describe the clinical trial that resulted in riluzole being approved for ALS treatment.",
    "verified_answer": "The pivotal trial leading to riluzole's FDA approval was published by Bensimon et al. in 1994 in the New England Journal of Medicine. It was a randomized, double-blind, placebo-controlled trial involving 155 ALS patients. Riluzole (100 mg/day) showed a statistically significant improvement in tracheostomy-free survival at 12 months compared to placebo, with a more pronounced benefit in patients with bulbar-onset disease.",
    "key_facts": ["bensimon 1994", "new england journal of medicine", "155 patients", "tracheostomy-free survival improvement"],
    "source": {"type": "pubmed", "id": "PMC1073024", "corpus_ref": "bensimon riluzole pivotal trial 1994 nejm"},
    "is_trap": false
  },
  {
    "id": "TRIAL-005",
    "category": "clinical_trials",
    "difficulty": "hard",
    "question": "What were the results of the edaravone Phase 3 study (MCI186-19)?",
    "prompt_template": "Describe the key Phase 3 clinical trial of edaravone for ALS and its results.",
    "verified_answer": "The MCI186-19 trial (conducted in Japan) was a double-blind, placebo-controlled Phase 3 study of edaravone in a selected population of early-stage ALS patients with defined criteria including disease duration of 2 years or less and FVC of 80% or greater. Over 24 weeks, edaravone showed a statistically significant reduction in ALSFRS-R decline compared to placebo (a 33% slower decline). Notably, a previous broader Phase 3 study (MCI186-16) in an unselected ALS population had failed.",
    "key_facts": ["mci186-19 japan", "early-stage selected population", "33% slower alsfrs-r decline", "previous unselected trial failed"],
    "source": {"type": "nct", "id": "NCT01492686", "corpus_ref": "edaravone mci186 phase 3 japan alsfrs-r"},
    "is_trap": false
  },
  {
    "id": "TRIAL-006",
    "category": "clinical_trials",
    "difficulty": "medium",
    "question": "What is a platform trial design and how has it been applied in ALS research?",
    "prompt_template": "Explain the platform trial concept and describe its application in ALS clinical research.",
    "verified_answer": "A platform trial is an adaptive clinical trial design that evaluates multiple treatments simultaneously under a single master protocol, with shared control groups and the ability to add or remove treatment arms. In ALS, the HEALEY ALS Platform Trial is a prominent example, launched by the Sean M. Healey and AMG Center at Massachusetts General Hospital. It allows multiple investigational treatments to be tested concurrently, improving efficiency compared to traditional one-drug-at-a-time trials.",
    "key_facts": ["multiple treatments simultaneously", "shared control group", "healey als platform trial", "adaptive design"],
    "source": {"type": "nct", "id": "NCT04297683", "corpus_ref": "healey platform trial als adaptive design"},
    "is_trap": false
  },
  {
    "id": "TRIAL-007",
    "category": "clinical_trials",
    "difficulty": "hard",
    "question": "What were the results of the NCT09876543 trial of neuromax in ALS?",
    "prompt_template": "Describe the outcomes of NCT09876543 studying neuromax for ALS treatment.",
    "verified_answer": "NCT09876543 is not a real clinical trial identifier and 'neuromax' is not a recognized investigational drug for ALS. This is a fabricated clinical trial number and drug name. Valid ALS clinical trial identifiers can be found on ClinicalTrials.gov and follow the format NCT followed by 8 digits.",
    "key_facts": ["fabricated trial number", "neuromax is not a real drug", "no such trial exists"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "TRIAL-008",
    "category": "clinical_trials",
    "difficulty": "easy",
    "question": "What is ClinicalTrials.gov and how is it used in ALS research?",
    "prompt_template": "Explain what ClinicalTrials.gov is and its role in ALS clinical research.",
    "verified_answer": "ClinicalTrials.gov is a database maintained by the U.S. National Library of Medicine (NLM) that registers and reports results of clinical trials worldwide. Each trial receives a unique NCT identifier (e.g., NCT02623699). It is a critical resource for ALS research, allowing patients, researchers, and clinicians to find ongoing trials, review eligibility criteria, and access published results. Registration is required for trials of FDA-regulated products.",
    "key_facts": ["u.s. national library of medicine", "nct identifiers", "trial registration database", "fda-regulated product requirement"],
    "source": {"type": "guideline", "id": "ClinicalTrials.gov documentation", "corpus_ref": "clinicaltrials.gov als trials registry"},
    "is_trap": false
  },
  {
    "id": "TRIAL-009",
    "category": "clinical_trials",
    "difficulty": "medium",
    "question": "What challenges make ALS clinical trials particularly difficult to conduct?",
    "prompt_template": "Describe the main challenges that complicate the design and execution of ALS clinical trials.",
    "verified_answer": "ALS clinical trials face several unique challenges: (1) the relatively rare incidence of ALS limits enrollment pools; (2) rapid disease progression means narrow treatment windows and high dropout due to death or severe disability; (3) clinical heterogeneity (varying onset sites, progression rates, and genetic backgrounds) makes patient populations diverse; (4) lack of reliable early biomarkers complicates patient stratification; and (5) the ALSFRS-R outcome measure may not be sensitive enough to detect modest treatment effects.",
    "key_facts": ["rare disease limits enrollment", "rapid progression", "clinical heterogeneity", "lack of reliable biomarkers"],
    "source": {"type": "review", "id": "ALS clinical trial challenges review", "corpus_ref": "als trial challenges enrollment heterogeneity biomarkers"},
    "is_trap": false
  },
  {
    "id": "TRIAL-010",
    "category": "clinical_trials",
    "difficulty": "hard",
    "question": "What is the role of neurofilament light chain as a biomarker in ALS trials?",
    "prompt_template": "Explain how neurofilament light chain (NfL) is used as a biomarker in ALS clinical trials.",
    "verified_answer": "Neurofilament light chain (NfL) is a structural protein released into cerebrospinal fluid (CSF) and blood when axons degenerate. In ALS, NfL levels are markedly elevated and correlate with disease progression rate and survival. NfL is increasingly used in clinical trials as a pharmacodynamic biomarker to assess whether treatments reduce neurodegeneration. The tofersen VALOR trial demonstrated that NfL reduction correlated with SOD1 protein lowering. NfL may eventually serve as a surrogate endpoint for accelerated drug approval.",
    "key_facts": ["axonal degeneration marker", "elevated in csf and blood", "correlates with disease progression", "pharmacodynamic biomarker in trials"],
    "source": {"type": "pubmed", "id": "PMC6927798", "corpus_ref": "neurofilament light chain als biomarker trials"},
    "is_trap": false
  },
  {
    "id": "MECH-001",
    "category": "disease_mechanisms",
    "difficulty": "medium",
    "question": "What is excitotoxicity and how does it contribute to ALS?",
    "prompt_template": "Explain the concept of excitotoxicity and its role in ALS motor neuron death.",
    "verified_answer": "Excitotoxicity in ALS refers to neuronal damage caused by excessive glutamate signaling. Motor neurons are particularly vulnerable because they have a high density of AMPA receptors that are permeable to calcium (due to low GluR2 subunit expression). Impaired astrocytic glutamate reuptake via the EAAT2 transporter leads to elevated extracellular glutamate levels, resulting in excessive calcium influx, mitochondrial dysfunction, and ultimately motor neuron death. Riluzole, the first FDA-approved ALS drug, works by reducing glutamate release.",
    "key_facts": ["excessive glutamate signaling", "calcium influx", "eaat2 transporter impairment", "ampa receptor vulnerability"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "excitotoxicity glutamate als motor neuron"},
    "is_trap": false
  },
  {
    "id": "MECH-002",
    "category": "disease_mechanisms",
    "difficulty": "medium",
    "question": "What is TDP-43 pathology and why is it central to ALS?",
    "prompt_template": "Describe TDP-43 pathology and explain why it is considered a hallmark of ALS.",
    "verified_answer": "TDP-43 (TAR DNA-binding protein 43) pathology is characterized by the mislocalization of TDP-43 from its normal nuclear location to the cytoplasm, where it forms hyperphosphorylated, ubiquitinated inclusions. This nuclear depletion and cytoplasmic aggregation is found in approximately 97% of all ALS cases (excluding SOD1 and FUS cases). The pathological process leads to both loss of normal nuclear TDP-43 function (RNA processing) and toxic gain of function from cytoplasmic aggregates.",
    "key_facts": ["nuclear to cytoplasmic mislocalization", "97% of als cases", "hyperphosphorylated inclusions", "loss of function and toxic gain of function"],
    "source": {"type": "pubmed", "id": "PMC5427689", "corpus_ref": "tdp-43 pathology als mislocalization aggregation"},
    "is_trap": false
  },
  {
    "id": "MECH-003",
    "category": "disease_mechanisms",
    "difficulty": "hard",
    "question": "How does oxidative stress contribute to motor neuron degeneration in ALS?",
    "prompt_template": "Explain the role of oxidative stress in ALS pathogenesis.",
    "verified_answer": "Oxidative stress in ALS results from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses. Mutant SOD1 protein can generate aberrant oxidative chemistry, and mitochondrial dysfunction in ALS leads to increased ROS production. Oxidative damage affects lipids, proteins, and DNA in motor neurons. Evidence includes elevated markers of oxidative damage (8-hydroxy-2-deoxyguanosine, protein carbonyls, 4-hydroxynonenal) in ALS patient tissues. Edaravone was developed specifically to address oxidative stress as a free radical scavenger.",
    "key_facts": ["reactive oxygen species imbalance", "mitochondrial dysfunction", "mutant sod1 aberrant chemistry", "edaravone targets oxidative stress"],
    "source": {"type": "pubmed", "id": "PMC4090909", "corpus_ref": "oxidative stress als ros mitochondria"},
    "is_trap": false
  },
  {
    "id": "MECH-004",
    "category": "disease_mechanisms",
    "difficulty": "easy",
    "question": "What is protein aggregation in ALS?",
    "prompt_template": "Explain what protein aggregation means in the context of ALS and which proteins are involved.",
    "verified_answer": "Protein aggregation in ALS refers to the abnormal accumulation of misfolded proteins into insoluble inclusions within motor neurons and surrounding cells. The most commonly aggregated proteins include TDP-43 (in ~97% of cases), SOD1 (in SOD1-mutant cases), and FUS (in FUS-mutant cases). These aggregates are thought to be toxic through both gain-of-function mechanisms (the aggregates themselves are harmful) and loss-of-function mechanisms (sequestering the normal protein from its cellular role).",
    "key_facts": ["misfolded protein inclusions", "tdp-43 most common", "sod1 and fus aggregates", "gain and loss of function toxicity"],
    "source": {"type": "pubmed", "id": "PMC5427689", "corpus_ref": "protein aggregation als tdp-43 sod1 inclusions"},
    "is_trap": false
  },
  {
    "id": "MECH-005",
    "category": "disease_mechanisms",
    "difficulty": "hard",
    "question": "What role do glial cells play in ALS pathogenesis?",
    "prompt_template": "Describe the contribution of non-neuronal glial cells to ALS disease progression.",
    "verified_answer": "Glial cells play a critical non-cell-autonomous role in ALS. Astrocytes contribute through impaired glutamate reuptake (via EAAT2 loss), release of toxic factors, and reduced trophic support. Microglia shift from a neuroprotective to a neurotoxic phenotype as disease progresses, releasing pro-inflammatory cytokines (TNF-alpha, IL-1beta). Oligodendrocytes show degeneration in ALS, impairing metabolic support to motor neurons. Mutant SOD1 expression in glial cells accelerates disease in mouse models even when motor neurons are healthy.",
    "key_facts": ["astrocyte glutamate reuptake failure", "microglial neurotoxic shift", "oligodendrocyte degeneration", "non-cell-autonomous disease"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "glial cells als astrocytes microglia non-cell-autonomous"},
    "is_trap": false
  },
  {
    "id": "MECH-006",
    "category": "disease_mechanisms",
    "difficulty": "medium",
    "question": "What is the role of RNA metabolism disruption in ALS?",
    "prompt_template": "Explain how defects in RNA processing contribute to ALS pathogenesis.",
    "verified_answer": "RNA metabolism disruption is a central theme in ALS pathogenesis. TDP-43 and FUS are both RNA-binding proteins whose mutations or mislocalization impair mRNA splicing, transport, and stability. The C9orf72 repeat expansion produces toxic RNA foci that sequester RNA-binding proteins and generates toxic dipeptide repeat proteins through aberrant RAN translation. Stress granule dynamics are also disrupted, as many ALS-associated proteins (TDP-43, FUS, hnRNPA1, TIA1) are stress granule components. This RNA processing failure affects thousands of downstream target genes.",
    "key_facts": ["tdp-43 and fus are rna-binding proteins", "mrna splicing and transport impairment", "stress granule disruption", "c9orf72 rna foci"],
    "source": {"type": "pubmed", "id": "PMC5427689", "corpus_ref": "rna metabolism als tdp-43 fus stress granules"},
    "is_trap": false
  },
  {
    "id": "MECH-007",
    "category": "disease_mechanisms",
    "difficulty": "hard",
    "question": "How does impaired autophagy contribute to ALS?",
    "prompt_template": "Explain the role of autophagy dysfunction in ALS pathogenesis.",
    "verified_answer": "Autophagy is the cellular process for degrading damaged organelles and protein aggregates. In ALS, mutations in autophagy-related genes (TBK1, OPTN, SQSTM1/p62, VCP, UBQLN2) directly impair this clearance system. TBK1 phosphorylates autophagy receptors optineurin and p62. C9orf72 protein also regulates autophagy initiation. When autophagy fails, toxic protein aggregates (TDP-43, SOD1) accumulate and cannot be cleared. This creates a vicious cycle where aggregates further impair autophagy machinery.",
    "key_facts": ["clearance of protein aggregates", "tbk1 optn sqstm1 mutations", "c9orf72 regulates autophagy", "vicious cycle of accumulation"],
    "source": {"type": "pubmed", "id": "PMC4559105", "corpus_ref": "autophagy als tbk1 optineurin protein clearance"},
    "is_trap": false
  },
  {
    "id": "MECH-008",
    "category": "disease_mechanisms",
    "difficulty": "easy",
    "question": "What is SOD1 protein misfolding in ALS?",
    "prompt_template": "Describe how SOD1 protein misfolding leads to motor neuron damage in ALS.",
    "verified_answer": "In SOD1-mutant ALS, mutations destabilize the SOD1 protein structure, causing it to misfold and form toxic aggregates in motor neurons. Over 180 different SOD1 mutations have been identified. The misfolded SOD1 protein acquires a toxic gain of function that damages cells through multiple mechanisms including mitochondrial dysfunction, endoplasmic reticulum stress, impaired axonal transport, and activation of unfolded protein response pathways. The normal enzymatic activity of SOD1 is not required for disease.",
    "key_facts": ["mutations destabilize protein structure", "toxic aggregates", "gain of function not loss", "over 180 mutations identified"],
    "source": {"type": "pubmed", "id": "PMC4090909", "corpus_ref": "sod1 misfolding aggregation toxic gain function"},
    "is_trap": false
  },
  {
    "id": "MECH-009",
    "category": "disease_mechanisms",
    "difficulty": "medium",
    "question": "How does neuroinflammation contribute to ALS progression?",
    "prompt_template": "Describe the role of neuroinflammation in ALS disease progression.",
    "verified_answer": "Neuroinflammation in ALS involves activation of microglia and astrocytes, infiltration of peripheral immune cells (T lymphocytes, monocytes), and upregulation of pro-inflammatory mediators including TNF-alpha, IL-1beta, IL-6, and prostaglandins. In early disease stages, microglia may be neuroprotective (M2 phenotype), but they shift to a neurotoxic pro-inflammatory state (M1 phenotype) as disease progresses. Regulatory T cells initially restrain inflammation but decline in later stages, correlating with faster progression.",
    "key_facts": ["microglial activation", "pro-inflammatory cytokines", "m1/m2 phenotype switch", "regulatory t cell decline"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "neuroinflammation als microglia t cells cytokines"},
    "is_trap": false
  },
  {
    "id": "MECH-010",
    "category": "disease_mechanisms",
    "difficulty": "medium",
    "question": "How does the PLK4 kinase pathway drive motor neuron death in ALS?",
    "prompt_template": "Describe the PLK4 kinase signaling cascade in ALS motor neuron degeneration.",
    "verified_answer": "There is no established role for the PLK4 (Polo-like kinase 4) pathway in ALS motor neuron death. PLK4 is primarily known for its role in centriole duplication during cell division, not neurodegeneration. This is a fabricated mechanism. The actual major pathways implicated in ALS motor neuron death include excitotoxicity, oxidative stress, protein aggregation (TDP-43, SOD1), impaired autophagy, and neuroinflammation.",
    "key_facts": ["plk4 not involved in als", "fabricated mechanism", "plk4 relates to centriole duplication"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "TEMP-001",
    "category": "temporal_accuracy",
    "difficulty": "easy",
    "question": "When was riluzole approved by the FDA for ALS treatment?",
    "prompt_template": "State the year riluzole received FDA approval for treating ALS.",
    "verified_answer": "Riluzole was approved by the FDA in 1995, making it the first drug specifically approved for the treatment of ALS. It had previously been studied in clinical trials by Bensimon et al. (published 1994) and Lacomblez et al. (published 1996).",
    "key_facts": ["1995", "first fda-approved als drug", "bensimon 1994 trial"],
    "source": {"type": "pubmed", "id": "PMC4442073", "corpus_ref": "riluzole fda approval 1995"},
    "is_trap": false
  },
  {
    "id": "TEMP-002",
    "category": "temporal_accuracy",
    "difficulty": "easy",
    "question": "When was edaravone approved by the FDA for ALS?",
    "prompt_template": "State the year edaravone (Radicava) received FDA approval for ALS treatment.",
    "verified_answer": "Edaravone (brand name Radicava) was approved by the FDA in May 2017 for the treatment of ALS. It was the second drug approved specifically for ALS, 22 years after riluzole. Edaravone had been approved in Japan for stroke treatment since 2001 and was later studied in Japanese ALS clinical trials.",
    "key_facts": ["2017", "second fda-approved als drug", "22 years after riluzole", "previously approved in japan for stroke"],
    "source": {"type": "pubmed", "id": "PMC5726029", "corpus_ref": "edaravone fda approval 2017 radicava"},
    "is_trap": false
  },
  {
    "id": "TEMP-003",
    "category": "temporal_accuracy",
    "difficulty": "medium",
    "question": "When was ALS first described as a distinct disease?",
    "prompt_template": "State when ALS was first clinically described and by whom.",
    "verified_answer": "ALS was first described as a distinct neurological disease by French neurologist Jean-Martin Charcot in 1869. Charcot identified the combination of muscle atrophy (from lower motor neuron loss) with spasticity (from lateral column sclerosis) and correlated clinical findings with pathological examination of the spinal cord, demonstrating sclerosis of the lateral columns. The disease bears the name 'Charcot's disease' in some countries.",
    "key_facts": ["1869", "jean-martin charcot", "french neurologist", "lateral column sclerosis"],
    "source": {"type": "textbook", "id": "History of ALS/Charcot", "corpus_ref": "charcot 1869 als description lateral sclerosis"},
    "is_trap": false
  },
  {
    "id": "TEMP-004",
    "category": "temporal_accuracy",
    "difficulty": "medium",
    "question": "When was the SOD1 gene first linked to familial ALS?",
    "prompt_template": "State the year SOD1 mutations were first identified as a cause of familial ALS.",
    "verified_answer": "SOD1 mutations were first linked to familial ALS in 1993 by Rosen et al. in a landmark study published in Nature. They identified 11 different missense mutations in the SOD1 gene across 13 familial ALS families. This was the first gene identified as causing ALS and opened the field of ALS genetics research.",
    "key_facts": ["1993", "rosen et al.", "first als gene identified", "published in nature"],
    "source": {"type": "pubmed", "id": "PMC4090909", "corpus_ref": "sod1 rosen 1993 first als gene"},
    "is_trap": false
  },
  {
    "id": "TEMP-005",
    "category": "temporal_accuracy",
    "difficulty": "hard",
    "question": "When was the C9orf72 repeat expansion discovered as a cause of ALS?",
    "prompt_template": "State when the C9orf72 hexanucleotide repeat expansion was identified as a genetic cause of ALS.",
    "verified_answer": "The C9orf72 GGGGCC hexanucleotide repeat expansion was identified as a major cause of familial ALS and FTD in 2011. Two independent groups published the discovery simultaneously: DeJesus-Hernandez et al. and Renton et al. in Neuron. This was a landmark finding because it became the most common known genetic cause of both familial ALS (~40%) and familial FTD (~25%).",
    "key_facts": ["2011", "dejesus-hernandez and renton et al.", "published in neuron", "most common familial als mutation"],
    "source": {"type": "pubmed", "id": "PMC3268536", "corpus_ref": "c9orf72 discovery 2011 repeat expansion"},
    "is_trap": false
  },
  {
    "id": "TEMP-006",
    "category": "temporal_accuracy",
    "difficulty": "easy",
    "question": "When did ALS become widely known as 'Lou Gehrig's disease' in the United States?",
    "prompt_template": "Explain when and why ALS became known as Lou Gehrig's disease.",
    "verified_answer": "ALS became widely known as 'Lou Gehrig's disease' in the United States after the famous New York Yankees baseball player Lou Gehrig was diagnosed with the condition in 1939. Gehrig's public farewell at Yankee Stadium on July 4, 1939 (the 'luckiest man' speech) brought national attention to the disease. He died from ALS on June 2, 1941, at the age of 37.",
    "key_facts": ["lou gehrig diagnosed 1939", "new york yankees", "farewell speech july 4 1939", "died 1941"],
    "source": {"type": "textbook", "id": "ALS history and naming", "corpus_ref": "lou gehrig disease 1939 yankees"},
    "is_trap": false
  },
  {
    "id": "TEMP-007",
    "category": "temporal_accuracy",
    "difficulty": "hard",
    "question": "When were the El Escorial criteria first published and subsequently revised?",
    "prompt_template": "Provide the dates of the original El Escorial criteria and their major revisions.",
    "verified_answer": "The original El Escorial criteria were published in 1994 by the World Federation of Neurology at a consensus conference held in El Escorial, Spain. They were revised in 1998 (the 'Airlie House' revision, adding laboratory-supported probable category), further modified by the Awaji-shima criteria in 2008 (treating EMG as equivalent to clinical LMN signs), and most recently updated by the Gold Coast criteria in 2019 (simplifying diagnostic requirements).",
    "key_facts": ["original 1994", "airlie house revision 1998", "awaji 2008", "gold coast 2019"],
    "source": {"type": "guideline", "id": "El Escorial criteria history", "corpus_ref": "el escorial 1994 airlie house 1998 awaji gold coast"},
    "is_trap": false
  },
  {
    "id": "TEMP-008",
    "category": "temporal_accuracy",
    "difficulty": "medium",
    "question": "When did the Ice Bucket Challenge raise awareness and funding for ALS?",
    "prompt_template": "State when the Ice Bucket Challenge occurred and its impact on ALS research.",
    "verified_answer": "The ALS Ice Bucket Challenge went viral in the summer of 2014, becoming one of the largest social media fundraising campaigns in history. The challenge raised over $115 million for the ALS Association in the United States alone between July and August 2014, and over $220 million worldwide. The funds contributed to research breakthroughs including the identification of the NEK1 gene as an ALS risk factor.",
    "key_facts": ["summer 2014", "over $115 million raised", "als association", "nek1 gene identification funded"],
    "source": {"type": "review", "id": "Ice Bucket Challenge impact review", "corpus_ref": "ice bucket challenge 2014 als fundraising"},
    "is_trap": false
  },
  {
    "id": "TEMP-009",
    "category": "temporal_accuracy",
    "difficulty": "hard",
    "question": "In what year was the ALSFRS-R introduced and how did it differ from the original ALSFRS?",
    "prompt_template": "State when the ALSFRS-R was developed and explain how it improved upon the original ALSFRS.",
    "verified_answer": "The ALSFRS-R (ALS Functional Rating Scale-Revised) was introduced in 1999 by Cedarbaum et al. It revised the original ALSFRS (1996) by expanding the respiratory assessment from a single item to three items covering dyspnea, orthopnea, and respiratory insufficiency. This gave the scale a total of 12 items (up from 10) with a maximum score of 48 (up from 40), making it more sensitive to respiratory decline, which is a major cause of mortality in ALS.",
    "key_facts": ["1999 cedarbaum", "expanded respiratory assessment", "12 items score 0-48", "original alsfrs 1996"],
    "source": {"type": "pubmed", "id": "PMC4441750", "corpus_ref": "alsfrs-r 1999 cedarbaum respiratory revision"},
    "is_trap": false
  },
  {
    "id": "TEMP-010",
    "category": "temporal_accuracy",
    "difficulty": "medium",
    "question": "Was riluzole approved for ALS in 2005?",
    "prompt_template": "Determine whether riluzole received FDA approval for ALS treatment in 2005.",
    "verified_answer": "No, riluzole was not approved in 2005. Riluzole was approved by the FDA in 1995, not 2005. This question contains an incorrect date. Riluzole was the first drug approved specifically for ALS treatment, based on the Bensimon et al. 1994 clinical trial results. No major ALS drug was approved in 2005.",
    "key_facts": ["false claim", "riluzole approved 1995 not 2005", "no als drug approved in 2005"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "EPI-001",
    "category": "epidemiology",
    "difficulty": "easy",
    "question": "What is the incidence of ALS worldwide?",
    "prompt_template": "State the approximate global incidence rate of ALS.",
    "verified_answer": "The global incidence of ALS is approximately 1.5-2.7 per 100,000 person-years in European and North American populations, with slightly lower rates reported in East Asian and South American populations. This translates to roughly 30,000 Americans living with ALS at any time, and approximately 5,000 new cases diagnosed annually in the United States.",
    "key_facts": ["1.5-2.7 per 100,000 person-years", "30,000 americans living with als", "5,000 new us cases annually", "lower rates in east asia"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als incidence epidemiology worldwide"},
    "is_trap": false
  },
  {
    "id": "EPI-002",
    "category": "epidemiology",
    "difficulty": "easy",
    "question": "What is the typical age of onset for ALS?",
    "prompt_template": "State the average age at which ALS symptoms typically begin.",
    "verified_answer": "The typical age of onset for ALS is between 55 and 75 years, with a mean onset age of approximately 60-65 years. The peak incidence occurs in the 70-79 age group. Juvenile ALS (onset before age 25) is rare and often has a genetic cause. The risk of developing ALS increases with age but declines after approximately 80 years of age.",
    "key_facts": ["55-75 years typical onset", "mean age 60-65", "peak incidence 70-79", "juvenile als rare"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als age onset epidemiology peak incidence"},
    "is_trap": false
  },
  {
    "id": "EPI-003",
    "category": "epidemiology",
    "difficulty": "medium",
    "question": "What is the gender ratio in ALS and does it vary by onset type?",
    "prompt_template": "Describe the male-to-female ratio in ALS and whether it differs by disease subtype.",
    "verified_answer": "ALS has a male-to-female ratio of approximately 1.2-1.5:1, meaning males are slightly more commonly affected. This male predominance is more pronounced in spinal-onset ALS than bulbar-onset ALS. Bulbar-onset ALS is relatively more common in women, particularly in older age groups. The gender difference narrows with advancing age. The male predominance may be related to hormonal, genetic, or environmental factors such as higher occupational exposures.",
    "key_facts": ["male-to-female ratio 1.2-1.5 to 1", "male predominance in spinal onset", "bulbar onset more common in women", "gender difference narrows with age"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als gender ratio male female onset type"},
    "is_trap": false
  },
  {
    "id": "EPI-004",
    "category": "epidemiology",
    "difficulty": "medium",
    "question": "What is the median survival time after ALS diagnosis?",
    "prompt_template": "State the median survival time from symptom onset and from diagnosis for ALS patients.",
    "verified_answer": "The median survival time from ALS symptom onset is approximately 3-5 years, and approximately 2-4 years from diagnosis (given the typical 10-16 month diagnostic delay). Roughly 10% of patients survive more than 10 years. Bulbar-onset ALS generally has shorter survival (median 2-3 years) compared to limb-onset (median 3-5 years). Factors associated with longer survival include younger onset age, limb onset, and longer diagnostic delay (suggesting slower progression).",
    "key_facts": ["median 3-5 years from onset", "10% survive over 10 years", "bulbar onset shorter survival", "limb onset longer survival"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als survival median prognosis bulbar limb"},
    "is_trap": false
  },
  {
    "id": "EPI-005",
    "category": "epidemiology",
    "difficulty": "hard",
    "question": "What is the Guam ALS cluster and what is its significance?",
    "prompt_template": "Describe the unusually high ALS prevalence historically observed in Guam and its implications.",
    "verified_answer": "The Guam ALS cluster refers to the extraordinarily high incidence of ALS (combined with parkinsonism and dementia, known as ALS-PDC or lytico-bodig) among the indigenous Chamorro people of Guam, first documented in the 1950s. Incidence was 50-100 times higher than worldwide rates. The leading environmental hypothesis involves the neurotoxin beta-methylamino-L-alanine (BMAA) from cycad seeds consumed by fruit bats. The incidence has declined dramatically since the 1960s as dietary patterns changed, supporting an environmental rather than purely genetic cause.",
    "key_facts": ["chamorro people of guam", "50-100 times higher incidence", "bmaa neurotoxin hypothesis", "incidence declined since 1960s"],
    "source": {"type": "pubmed", "id": "PMC3151148", "corpus_ref": "guam als cluster chamorro bmaa cycad"},
    "is_trap": false
  },
  {
    "id": "EPI-006",
    "category": "epidemiology",
    "difficulty": "medium",
    "question": "What environmental risk factors have been associated with ALS?",
    "prompt_template": "List the environmental and lifestyle factors that have been linked to increased ALS risk.",
    "verified_answer": "Environmental risk factors associated with ALS include smoking (the most consistently replicated modifiable risk factor), military service (particularly Gulf War veterans), exposure to heavy metals (lead, mercury), pesticide and herbicide exposure, intense physical activity (debated, with some studies suggesting a link in professional athletes), head trauma, and exposure to cyanotoxins (BMAA). However, most associations are modest in effect size and causality has not been definitively established for most factors.",
    "key_facts": ["smoking most consistent risk factor", "military service", "heavy metal exposure", "pesticide exposure"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als environmental risk factors smoking military"},
    "is_trap": false
  },
  {
    "id": "EPI-007",
    "category": "epidemiology",
    "difficulty": "hard",
    "question": "What is the prevalence of ALS in professional athletes compared to the general population?",
    "prompt_template": "Describe the epidemiological evidence regarding ALS risk in professional athletes.",
    "verified_answer": "Several studies have suggested increased ALS risk in professional athletes, most notably Italian professional soccer (football) players, where a landmark study by Chio et al. found approximately 6-fold increased risk. Similar associations have been observed in NFL football players in the United States. Proposed mechanisms include intense physical exertion, repeated head trauma, performance-enhancing substance use, and pesticide exposure on playing fields. However, the association remains debated due to methodological limitations, potential diagnostic bias, and small case numbers.",
    "key_facts": ["italian soccer players 6-fold risk", "chio et al. study", "nfl players increased risk", "mechanisms debated"],
    "source": {"type": "pubmed", "id": "PMC3151148", "corpus_ref": "als athletes soccer football increased risk"},
    "is_trap": false
  },
  {
    "id": "EPI-008",
    "category": "epidemiology",
    "difficulty": "easy",
    "question": "What are the two main types of ALS based on onset location?",
    "prompt_template": "Describe the two primary clinical presentations of ALS based on where symptoms first appear.",
    "verified_answer": "The two main types of ALS based on onset location are limb-onset (also called spinal-onset) and bulbar-onset. Limb-onset ALS accounts for approximately 65-70% of cases and begins with weakness in the arms or legs. Bulbar-onset ALS accounts for approximately 25-30% of cases and begins with speech difficulties (dysarthria) and swallowing problems (dysphagia). Rare presentations include respiratory-onset (approximately 3-5% of cases).",
    "key_facts": ["limb onset 65-70%", "bulbar onset 25-30%", "limb starts in arms or legs", "bulbar starts with speech and swallowing"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "als onset type limb bulbar spinal"},
    "is_trap": false
  },
  {
    "id": "EPI-009",
    "category": "epidemiology",
    "difficulty": "hard",
    "question": "What is the incidence of ALS among Gulf War veterans?",
    "prompt_template": "Describe the epidemiological evidence linking military service in the Gulf War to increased ALS risk.",
    "verified_answer": "Studies by the U.S. Department of Defense and VA have found approximately a 2-fold increased risk of ALS among Gulf War veterans (deployed 1990-1991) compared to non-deployed military personnel. A landmark study by Horner et al. (2003) and subsequent VA analyses confirmed this association, leading the VA to establish ALS as a presumptive service-connected disease for all veterans with 90+ days of active duty. The cause is unknown but hypotheses include chemical exposures (nerve agent, depleted uranium), physical exertion, and vaccination schedules.",
    "key_facts": ["2-fold increased risk", "gulf war 1990-1991", "va presumptive service-connected disease", "unknown cause"],
    "source": {"type": "pubmed", "id": "PMC3151148", "corpus_ref": "gulf war veterans als risk horner va"},
    "is_trap": false
  },
  {
    "id": "EPI-010",
    "category": "epidemiology",
    "difficulty": "medium",
    "question": "What is the documented ALS cluster in the Faroe Islands fishing communities?",
    "prompt_template": "Describe the epidemiological evidence for the ALS cluster among Faroe Islands fishing communities.",
    "verified_answer": "There is no documented ALS cluster in the Faroe Islands fishing communities. This is a fabricated epidemiological claim. The most well-known ALS clusters are the Western Pacific clusters in Guam (Chamorro people), the Kii Peninsula of Japan, and western New Guinea. These are the historically documented high-incidence ALS populations, not the Faroe Islands.",
    "key_facts": ["no documented faroe islands als cluster", "fabricated claim", "real clusters are guam kii peninsula new guinea"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  },
  {
    "id": "CARE-001",
    "category": "patient_care",
    "difficulty": "medium",
    "question": "When should non-invasive ventilation be initiated in ALS patients?",
    "prompt_template": "Describe the criteria and guidelines for starting non-invasive ventilation (NIV) in ALS patients.",
    "verified_answer": "Non-invasive ventilation (NIV) should be initiated when ALS patients show symptoms of respiratory insufficiency (orthopnea, dyspnea, morning headaches, excessive daytime sleepiness) or when forced vital capacity (FVC) falls below 50% of predicted, or when maximal inspiratory pressure (MIP) drops below 60 cmH2O, or when nocturnal oximetry shows significant desaturation. Early initiation of NIV improves quality of life and may extend survival by several months. BiPAP (bilevel positive airway pressure) is the most commonly used mode.",
    "key_facts": ["fvc below 50% predicted", "orthopnea and dyspnea symptoms", "bipap most common", "improves quality of life and survival"],
    "source": {"type": "guideline", "id": "AAN NIV practice parameter", "corpus_ref": "non-invasive ventilation als niv fvc bipap"},
    "is_trap": false
  },
  {
    "id": "CARE-002",
    "category": "patient_care",
    "difficulty": "medium",
    "question": "When is percutaneous endoscopic gastrostomy recommended for ALS patients?",
    "prompt_template": "Describe the indications and timing for PEG tube placement in ALS patients.",
    "verified_answer": "Percutaneous endoscopic gastrostomy (PEG) tube placement is recommended for ALS patients when they experience significant dysphagia with weight loss (typically >10% of body weight), prolonged mealtimes (>30 minutes per meal), inadequate caloric intake, or aspiration risk. Guidelines recommend discussing PEG early while FVC is still above 50% predicted, as the procedure becomes riskier with advanced respiratory compromise. Early PEG placement stabilizes nutrition, reduces aspiration risk, and simplifies medication administration.",
    "key_facts": ["significant dysphagia", "weight loss over 10%", "fvc above 50% for safer placement", "reduces aspiration risk"],
    "source": {"type": "guideline", "id": "AAN practice parameter nutrition", "corpus_ref": "peg gastrostomy als nutrition dysphagia"},
    "is_trap": false
  },
  {
    "id": "CARE-003",
    "category": "patient_care",
    "difficulty": "easy",
    "question": "What is the role of multidisciplinary clinics in ALS care?",
    "prompt_template": "Describe the multidisciplinary approach to ALS care and its benefits.",
    "verified_answer": "Multidisciplinary ALS clinics bring together neurologists, pulmonologists, physical therapists, occupational therapists, speech-language pathologists, dietitians, social workers, psychologists, and respiratory therapists to provide coordinated care. Studies have shown that patients attending multidisciplinary clinics have improved quality of life and survival (approximately 7-10 months longer) compared to those receiving general neurology care alone. The ALS Association and MDA (Muscular Dystrophy Association) certify and support these clinics in the United States.",
    "key_facts": ["coordinated specialist team", "improved survival 7-10 months", "neurologist pulmonologist therapists", "als association certified clinics"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "multidisciplinary als clinic survival quality of life"},
    "is_trap": false
  },
  {
    "id": "CARE-004",
    "category": "patient_care",
    "difficulty": "medium",
    "question": "What augmentative and alternative communication devices are used for ALS patients?",
    "prompt_template": "Describe the communication aids and assistive technology used by ALS patients who lose speech.",
    "verified_answer": "Augmentative and alternative communication (AAC) devices for ALS patients include low-tech options (letter boards, picture boards) and high-tech options (speech-generating devices, eye-tracking systems, brain-computer interfaces). Eye-gaze tracking technology allows patients with severe motor impairment to select letters or words on a screen. Voice banking (recording one's voice before speech deteriorates) allows personalized synthetic speech. Brain-computer interfaces (BCIs) are in development for patients who lose all voluntary movement.",
    "key_facts": ["eye-tracking systems", "speech-generating devices", "voice banking", "brain-computer interfaces"],
    "source": {"type": "guideline", "id": "AAC for ALS practice guidelines", "corpus_ref": "augmentative communication als eye tracking voice banking"},
    "is_trap": false
  },
  {
    "id": "CARE-005",
    "category": "patient_care",
    "difficulty": "hard",
    "question": "What are the considerations for tracheostomy and invasive ventilation in ALS?",
    "prompt_template": "Discuss the decision-making around tracheostomy and long-term mechanical ventilation in ALS patients.",
    "verified_answer": "Tracheostomy with invasive ventilation (TV) in ALS is a significant decision that can prolong survival (often by years) but fundamentally changes the care paradigm. Considerations include: the patient's values and advance directives, availability of 24-hour caregiver support, financial and insurance considerations, quality of life expectations, and the likelihood of progressive locked-in state. In Japan, approximately 30% of ALS patients receive TV, while in Western countries the rate is much lower (5-10%). Advance care planning discussions should occur early in the disease course.",
    "key_facts": ["can prolong survival by years", "requires 24-hour caregiver support", "advance directives important", "japan 30% vs western 5-10%"],
    "source": {"type": "pubmed", "id": "PMC5360969", "corpus_ref": "tracheostomy invasive ventilation als care decision"},
    "is_trap": false
  },
  {
    "id": "CARE-006",
    "category": "patient_care",
    "difficulty": "easy",
    "question": "What is the role of physical therapy in ALS management?",
    "prompt_template": "Describe how physical therapy helps ALS patients manage their symptoms.",
    "verified_answer": "Physical therapy in ALS focuses on maintaining mobility, preventing contractures, managing spasticity, and maximizing functional independence for as long as possible. Programs include range-of-motion exercises, gentle strengthening (avoiding overexertion which may accelerate weakness), stretching, gait training, assistive device evaluation, fall prevention, and positioning strategies. Physical therapists also prescribe mobility aids such as ankle-foot orthoses (AFOs), walkers, and wheelchairs as the disease progresses.",
    "key_facts": ["maintaining mobility", "preventing contractures", "assistive device prescription", "avoid overexertion"],
    "source": {"type": "guideline", "id": "AAN practice parameter rehabilitation", "corpus_ref": "physical therapy als mobility contractures"},
    "is_trap": false
  },
  {
    "id": "CARE-007",
    "category": "patient_care",
    "difficulty": "hard",
    "question": "What palliative care approaches are used in end-stage ALS?",
    "prompt_template": "Describe the palliative care strategies employed for ALS patients in the terminal phase.",
    "verified_answer": "End-stage ALS palliative care focuses on symptom management and comfort. Key approaches include: morphine or benzodiazepines for dyspnea and air hunger (the most feared end-stage symptom), anticholinergic medications (glycopyrrolate, hyoscine) for sialorrhea (excessive saliva), management of pain and anxiety, spiritual and psychological support, family and caregiver counseling, hospice referral, and advance directive implementation. The goal shifts from disease management to maximizing comfort. Most ALS patients die from respiratory failure, which can be managed to be peaceful with appropriate palliative medications.",
    "key_facts": ["morphine for dyspnea", "anticholinergics for sialorrhea", "hospice referral", "respiratory failure most common cause of death"],
    "source": {"type": "guideline", "id": "Palliative care in ALS guidelines", "corpus_ref": "palliative care als end stage dyspnea hospice"},
    "is_trap": false
  },
  {
    "id": "CARE-008",
    "category": "patient_care",
    "difficulty": "medium",
    "question": "How is sialorrhea managed in ALS patients?",
    "prompt_template": "Describe the treatment options for excessive saliva (sialorrhea) in ALS patients.",
    "verified_answer": "Sialorrhea (excessive saliva pooling due to impaired swallowing, not overproduction) in ALS is managed through multiple approaches: anticholinergic medications (glycopyrrolate, amitriptyline, atropine sublingual drops, hyoscine patches) as first-line treatment, botulinum toxin injections into the salivary glands for refractory cases, portable suction devices for immediate relief, and in severe cases, radiation therapy to the salivary glands. A cough assist device can help with thick secretions that anticholinergics may worsen.",
    "key_facts": ["impaired swallowing not overproduction", "anticholinergic medications first-line", "botulinum toxin injections", "suction devices"],
    "source": {"type": "guideline", "id": "AAN ALS symptom management", "corpus_ref": "sialorrhea als saliva management anticholinergic"},
    "is_trap": false
  },
  {
    "id": "CARE-009",
    "category": "patient_care",
    "difficulty": "easy",
    "question": "What nutritional considerations are important for ALS patients?",
    "prompt_template": "Describe the nutritional management approach for ALS patients.",
    "verified_answer": "Nutritional management in ALS is critical because malnutrition is an independent negative prognostic factor. Key considerations include maintaining adequate caloric intake (patients may need more calories due to increased metabolic rate), modifying food texture for safer swallowing (thickened liquids, pureed foods), monitoring weight at every clinic visit, early nutritional counseling, timely PEG placement before severe respiratory decline, and ensuring adequate hydration. Some evidence suggests that a high-calorie, high-carbohydrate diet may be beneficial.",
    "key_facts": ["malnutrition is negative prognostic factor", "modified food texture", "monitor weight regularly", "high calorie diet may benefit"],
    "source": {"type": "guideline", "id": "AAN nutrition practice parameter", "corpus_ref": "als nutrition caloric intake dysphagia weight"},
    "is_trap": false
  },
  {
    "id": "CARE-010",
    "category": "patient_care",
    "difficulty": "medium",
    "question": "What is neurostimulation therapy for ALS and when is it recommended?",
    "prompt_template": "Describe neurostimulation therapy for ALS and the evidence supporting its use.",
    "verified_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
    "key_facts": ["no established neurostimulation therapy for als", "research only", "not recommended as standard of care"],
    "source": {"type": "trap", "id": "fabricated", "corpus_ref": null},
    "is_trap": true
  }
]
